Literature DB >> 75504

Immunocytochemical identification of azurophilic and specific granule markers in the giant granules of Chediak-Higashi neutrophils.

P G Rausch, K B Pryzwansky, J K Spitznagel.   

Abstract

We used immunofluorescent microscopy to characterize the abnormal granules in neutrophils from five patients with Chediak-Higashi disease. Monospecific antiserums to the azurophilic markers myeloperoxidase, elastase, cathepsin G and lysozyme, and to the specific granule markers lactoferrin and lysozyme, were labeled with fluorescein and rhodamine and were used to demonstrate two antigens in the same cell simultaneously. The abnormal granules in Chediak-Higashi neutrophils contained both azurophilic and specific granule markers. Normal-appearing lactoferrin-positive granules were also present, but normal azurophilic granules were not seen. Analysis of bone-marrow samples from two of these patients suggested that the abnormal granules were formed during granulocyte maturation by the progressive aggregation and fusion of normally formed azurophilic and specific granules. These results are consistent with a membrane abnormality or a defect of microtubular function leading to inappropriate granule fusion, and suggest that the granular abnormality is more generalized than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 75504     DOI: 10.1056/NEJM197803302981301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration.

Authors:  Diana Amantea; Michelangelo Certo; Francesco Petrelli; Giacinto Bagetta
Journal:  Assay Drug Dev Technol       Date:  2016-07-08       Impact factor: 1.738

2.  Chédiak-Higashi syndrome neutrophils are characterized by the absence of both normal azurophilic granules.

Authors:  B C West
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

3.  Myeloperoxidase activity imaging using (67)Ga labeled substrate.

Authors:  Manel Querol Sans; John W Chen; Ralph Weissleder; Alexei A Bogdanov
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

4.  Characterization of lysosomes and lysosomal enzymes from Chediak-Higashi-syndrome cultured fibroblasts.

Authors:  A L Miller; R Stein; M Sundsmo; R Y Yeh
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

5.  Lactoferrin-deficient neutrophil polymorphonuclear leucocytes in leukaemias: a semiquantitative and ultrastructural cytochemical study.

Authors:  J Miyauchi; Y Watanabe; Y Enomoto; K Takeuchi
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

6.  Oxygen-independent intracellular and oxygen-dependent extracellular killing of Escherichia coli S15 by human polymorphonuclear leukocytes.

Authors:  J Weiss; L Kao; M Victor; P Elsbach
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound.

Authors:  Yu Kataoka; Mingyuan Shao; Kathy Wolski; Kiyoko Uno; Rishi Puri; E Murat Tuzcu; Stanley L Hazen; Steven E Nissen; Stephen J Nicholls
Journal:  Atherosclerosis       Date:  2013-12-19       Impact factor: 5.162

8.  Ultrastructure of resting and activated storage pool deficient platelets from animals with the Chédiak-Higashi syndrome.

Authors:  K M Meyers; G Hopkins; H Holmsen; K Benson; D J Prieur
Journal:  Am J Pathol       Date:  1982-03       Impact factor: 4.307

9.  Genetic disorders of leukocyte function: what they tell us about normal antimicrobial mechanisms of human phagocytic cells.

Authors:  R K Root; P B Beeson
Journal:  Klin Wochenschr       Date:  1982-07-15

10.  Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina.

Authors:  Xi-Qin Ding; Alexander B Quiambao; J Browning Fitzgerald; Mark J Cooper; Shannon M Conley; Muna I Naash
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.